Background: Pancreatic metastasis accounts for 2% to 11% of all mRCC cases. The prognostic value of pancreatic metastases in the era of TTs is unclear. We evaluated outcomes in a cohort of mRCC patients with pancreatic metastases (PmRCC) who were treated with TTs. Patients and Methods: We retrospectively reviewed the records of 354 mRCC patients treated at our institute between January 2005 and June 2012. Differences in terms of OS between this unselected cohort of mRCC patients and a subgroup of patients with PmRCC were investigated. Kaplan-Meier and log-rank test methods were used to evaluate OS. Results: In total, 24 PmRCC (7%) patients were identified, and were compared with a cohort of 330 mRCC patients with metastasis at other sites. Pancreatic metastases were synchronous in 3 patients, and they were metachronous in 11 patients. Surgical resection of pancreatic metastases was performed in 2 (8%) patients. At a maximum follow-up of 89 months (median, 51 months), median OS was 39 months in PmRCC patients, vs. 23 months in the mRCC patient group (P =.0004). Conclusion: Among mRCC patients treated with TTs, the presence of pancreatic metastasis seems to be associated with a longer survival than the presence of metastasis at other sites.

Prognostic role of pancreatic metastases from renal cell carcinoma : Results from an Italian center / P. Grassi, E. Verzoni, L. Mariani, F. De Braud, J. Coppa, V. Mazzaferro, G. Procopio. - In: CLINICAL GENITOURINARY CANCER. - ISSN 1558-7673. - 11:4(2013 Dec), pp. 484-488.

Prognostic role of pancreatic metastases from renal cell carcinoma : Results from an Italian center

E. Verzoni
Secondo
;
F. De Braud;V. Mazzaferro;
2013

Abstract

Background: Pancreatic metastasis accounts for 2% to 11% of all mRCC cases. The prognostic value of pancreatic metastases in the era of TTs is unclear. We evaluated outcomes in a cohort of mRCC patients with pancreatic metastases (PmRCC) who were treated with TTs. Patients and Methods: We retrospectively reviewed the records of 354 mRCC patients treated at our institute between January 2005 and June 2012. Differences in terms of OS between this unselected cohort of mRCC patients and a subgroup of patients with PmRCC were investigated. Kaplan-Meier and log-rank test methods were used to evaluate OS. Results: In total, 24 PmRCC (7%) patients were identified, and were compared with a cohort of 330 mRCC patients with metastasis at other sites. Pancreatic metastases were synchronous in 3 patients, and they were metachronous in 11 patients. Surgical resection of pancreatic metastases was performed in 2 (8%) patients. At a maximum follow-up of 89 months (median, 51 months), median OS was 39 months in PmRCC patients, vs. 23 months in the mRCC patient group (P =.0004). Conclusion: Among mRCC patients treated with TTs, the presence of pancreatic metastasis seems to be associated with a longer survival than the presence of metastasis at other sites.
mTOR inhibitors; pancreas; renal cell carcinoma; targeted therapy; tyrosine kinase inhibitors; adult; aged; aged, 80 and over; carcinoma, renal cell; cohort studies; female; humans; italy; kidney neoplasms; male; middle aged; molecular targeted therapy; pancreatic neoplasms; prognosis; retrospective studies; survival; oncology; urology
Settore MED/06 - Oncologia Medica
dic-2013
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1558767313000839-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 190.04 kB
Formato Adobe PDF
190.04 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/426928
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 40
social impact